Tesla to Build Mobile Molecule Printers to Develop COVID-19 Vaccine | Financial Buzz

Tesla to Build Mobile Molecule Printers to Develop COVID-19 Vaccine

Ribonucleic acid is a polymeric molecule essential in various biological roles in coding, decoding, regulation and expression of genes.

Tesla, Inc. (NASDAQ: TSLA) is structuring mobile molecule printers to help make potential coronavirus vaccine that is being developed by CureVac in Germany, Elon Musk tweeted on Wednesday.  Curevac has reported that its developing portable, automated mRNA production units that Musk has labeled as “RNA microfactories”.  It is designed to be shipped out to remote locations where it may churn out its vaccine candidate and other mRNA-based therapies depending on the formula utilized in the machine. 

In regards to the coronavirus pandemic, if its vaccine candidate gets approved, the company has production sites with regulatory approval in Germany that may produce hundreds of millions of doses.  CureVac is building a new stationary site that may increase its production output to billions of doses.

Microfactories will be built at the Tesla Grohmann Automation in Germany, Musk stated on Twitter.